scholarly journals Safety and Efficacy of Long-Term Use of Tolvaptan in Patients With Heart Failure and Chronic Kidney Disease

2017 ◽  
Vol 81 (11) ◽  
pp. 1736-1738 ◽  
Author(s):  
Yusuke Uemura ◽  
Rei Shibata ◽  
Kenji Takemoto ◽  
Tomohiro Uchikawa ◽  
Masayoshi Koyasu ◽  
...  
2018 ◽  
Vol 12 (3) ◽  
pp. 154-160
Author(s):  
Yohei Ono ◽  
Hiroto Takamatsu ◽  
Masahiro Inoue ◽  
Yukio Mabuchi ◽  
Tetsuya Ueda ◽  
...  

Nephrology ◽  
2016 ◽  
Vol 21 (6) ◽  
pp. 490-498 ◽  
Author(s):  
Carsten G. Jungbauer ◽  
Ekrem Uecer ◽  
Stefan Stadler ◽  
Christoph Birner ◽  
Stefan Buchner ◽  
...  

2018 ◽  
Vol 5 (2) ◽  
pp. 100-106 ◽  
Author(s):  
Kennosuke Yamashita ◽  
Wataru Igawa ◽  
Morio Ono ◽  
Takehiko Kido ◽  
Toshitaka Okabe ◽  
...  

Author(s):  
Aaron M. Hein ◽  
Julia J. Scialla ◽  
Jie-Lena Sun ◽  
Stephen J. Greene ◽  
Linda K. Shaw ◽  
...  

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Patrick M Hyland ◽  
Jiaman Xu ◽  
Changyu Shen ◽  
Lawrence Markson ◽  
Warren J Manning ◽  
...  

Introduction: The association between baseline patient characteristics and the long-term utilization of transthoracic echocardiography (TTE) is unknown and may help focus value-based care initiatives. Methods: TTE reports from patients with ≥ 2 TTEs at our institution were linked to 100% Medicare Fee-for-service inpatient claims, 1/1/2000 – 12/31/2017. To avoid inclusion of individuals with short-interval follow-up, TTEs with < 1 year between studies were excluded. Validated claims algorithms were used to create 12 baseline cardiovascular comorbidities. Multivariable Poisson regression was used to estimate adjusted rates of TTE intensity according to baseline comorbidities. Results: Over a median (IQR) follow-up of 5.8 (3.1 – 9.5) years, 18,579 individuals (69.3 ± 12.8 years; 50.5% female) underwent a total of 59,759 TTEs (range 2 – 59). The median TTE intensity was 0.64 TTEs/patient/year (IQR 0.35 – 1.24; range 0.11 – 22.02). The top five contributors to TTE intensity were heart failure, chronic kidney disease, history of myocardial infarction, smoking, and hyperlipidemia ( Figure ). Female sex was associated with decreased TTE utilization (adjusted RR 0.95, 95% CI 0.94-0.96, p < 0.0001). Atrial fibrillation, hypertension, and history of ischemic stroke or transient ischemic attack were not significantly related to TTE intensity after multivariable adjustment (all p > 0.05). Conclusions: Among Medicare beneficiaries with ≥ 2 TTEs at our institution, the median TTE intensity was 0.64 TTEs/patient/year but varied widely. Heart failure, chronic kidney disease, and history of myocardial infarction were the strongest predictors of increased utilization. Female sex was associated with decreased utilization, reflecting broader disparities in utilization of cardiovascular procedures. Further research is needed to clarify reasons for this sex disparity and associations with cardiovascular outcomes.


Sign in / Sign up

Export Citation Format

Share Document